Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (June 2026)
43 slides from Ac Immune Sa's shareholder meeting presentation, Jun 11, 2026
Slide 1: Pioneering Precision Prevention: Investor Update
PIONEERING PRECISION PREVENTION TARGETED THERAPEUTICS FOR NEURODEGENERATIVE DISEASES Investor Update NASDAQ: ACIU | Annual General Meeting – June 11, 2026 NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include s
Slide 3: Agenda
Agenda 1. AC Immune’s approach to neurodegenerative diseases 2. Achievements 2025 3. Business update 4. Key milestones 2026 5. Financial figures 6. Summary and Strategic outlook 7. Agenda items and proposals of the Board of Directors NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. N
Slide 4: 1. AC Immune's approach to neurodegenerative diseases
1. AC Immune’s approach to neurodegenerative diseases
Slide 5: AC Immune – pioneering precision prevention of neurodegeneration
AC Immune – pioneering precision prevention of neurodegeneration Next generation Precision Medicine for neurodegenerative diseases Focused pipeline with active immunotherapies and ■ Based in Lausanne, Switzerland intracellular targeted small molecule programs ■ ~120 employees ■ Listed on NASDAQ: ACI
Slide 6: 2. Achievements 2025
2. Achievements 2025
Slide 7: AC Immune 2025 highlights
AC Immune 2025 highlights Active immunotherapies Intracellular Targeting Finance Targeted active immunotherapies: Small molecule programs: Operating capital foundation: ▪ ACI-71041 (wholly-owned) ▪ Small molecule programs targeting ▪ Significant restructuring in Q3 2025 Phase 2 trial interims with T
Slide 8: 3. Business update
3. Business update
Slide 9: Our value drivers achieving Precision Prevention
Our value drivers achieving Precision Prevention through Active Immunotherapy complemented by Intracellular Targeting Active Immunotherapies Brain penetrant SM1 ACI-35.030 ACI-24.060 ACI-7104.056 Intracellular anti-pTau anti-Abeta anti-a-syn targeting The only active Biomarker-driven Active immunoth
Slide 10: Pipeline focused on Precision Prevention for neurodegenerative diseases
Pipeline focused on Precision Prevention for neurodegenerative diseases: Active Immunotherapies and Intracellular Targeting Modality Candidate Partner Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 ACI-35.030 (JNJ-2056) Alzheimer's disease (pTau1) FDA Fast Track Immunotherapy Alzheimer's d
Slide 11: Active immunotherapy programs
Active immunotherapy programs: Targeting Abeta, Tau, and a-syn
Slide 12: Active immunotherapy: major advantages
targeting neurodegenerative diseases Major advantages Active immunotherapy Long-lasting specific immunity for pathological target, consistent, boostable Stimulates the patient's immune system to Limited annual dosing (once or twice) after priming year produce their own antibodies No observed ARIA-E1
Slide 13: Active immunotherapies driving Precision Prevention
Active immunotherapies driving Precision Prevention Three clinical-stage programs supported by promising data from prior trials Candidate Indication Discovery Preclinical Phase 1 Phase 2 Status AD1 treatment FDA Fast Track Phase 1b/2 ABATE ACI-24 (anti-Abeta) trial ongoing AD treatment (Down syndrom
Slide 14: Active immunotherapy: a new class of treatment
Active immunotherapy: a new class of treatment for neurodegenerative disease Potential for profound social and economic impact Treatment Prevention Maintenance for global treatment and prevention of neurodegenerative diseases NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be
Slide 15: Small molecule programs
Small molecule programs: Targeting intracellular NLRP3, Tau, and a-syn
Slide 16: Intracellular Targeting for earliest pathology intervention
Intracellular Targeting for earliest pathology intervention in NDD1 Brain penetrant small molecules as a key differentiator 1 Optimal delivery into the central nervous system 2 Cell-penetrant with proven engagement of their specific intracellular target Conformation-specific and highly selective for
Slide 17: Intracellular Targeting pipeline
Intracellular Targeting pipeline focused on neurodegenerative diseases Programs now close supported by promising data from prior trials Candidate Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 ACI-19764 Neuro-inflammation (NLRP3 1) Morphomer® Tau Alzheimer's disease (Tau) Morphomer® a-syn2
Slide 18: 4. Key milestones 2026
4. Key milestones 2026
Slide 19: Key milestones 2026
Key milestones 2026 Readouts Multiple catalysts across pipeline Other development events Active immunotherapies H1 2026 H2 2026 ABATE Phase 2 trial in AD1: first patient dosed in AD4 cohort ACI-24 (Takeda) Abeta ABATE Phase 2 trial readouts after 12 months of treatment (AD3: Abeta PET) Discussions w
Slide 20: 5. Financial figures
5. Financial figures
Slide 21: 2025 Financial Overview
2025 Financial Overview Key financial data (IFRS) For the year ended December 31, 2025 2024 Change (in CHF million) (except per share data) Revenues 3.6 27.3 (23.7) R&D expenses (56.4) (62.6) 6.2 G&A expenses (16.1) (17.3) 1.2 Other operating income 0.1 0.1 0.0 Restructuring expenses, net (0.5) ─ (0
Slide 22: AC Immune strong Balance Sheet
AC Immune strong Balance Sheet Operations well-funded into Q4 2027 Cash of CHF 74.8 million1 Investment strategy focused 2026 annual cash burn guidance CHF 55m – 65m on major value drivers and near- term catalysts Strong Balance Sheet2 Cash runway into Q4 2027 (1) As of March 31, 2026; (2) Assumes n
Slide 23: 6. Summary and Strategic outlook
6. Summary and Strategic outlook
Slide 24: Creating the future of Precision Medicine in neurodegeneration
Creating the future of Precision Medicine in neurodegeneration The foundation for early detection and treatment Advance clinical-stage Valorize Morphomer® Financial active immunotherapies small molecule platform position Targeted active immunotherapies: Intracellular targeting assets: Operating capi
Slide 25: Pioneering Precision Prevention
Pioneering Precision Prevention Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 25
Slide 26: 7. Agenda items and proposals of the Board of Directors
7. Agenda items and proposals of the Board of Directors
Slide 27: Agenda item 1.1: Approval of 2025 financial statements
Agenda item 1 2025 IFRS Consolidated Financial Statements, 2025 Statutory Financial Statements, 2025 Compensation Report 1.1 Approval of 2025 IFRS Consolidated Financial Statements and 2025 Statutory Financial Statements ■ The Board proposes that the 2025 IFRS Consolidated Financial Statements and t
Slide 28: Agenda item 1.2: Advisory vote on Compensation Report
Agenda item 1 2025 IFRS Consolidated Financial Statements, 2025 Statutory Financial Statements, 2025 Compensation Report 1.2 Advisory Vote on the 2025 Compensation Report ■ The Board proposes that the 2025 Compensation Report be endorsed (non-binding advisory vote) NASDAQ: ACIU | AGM Presentation, J
Slide 29: Agenda item 2: Appropriation of Losses
Agenda item 2 Appropriation of Losses ■ The Board proposes the following appropriation of losses: In CHF K Accumulated profit (loss) at Jan 1, 2025 (356,846) Net profit (loss) for the year 2025 (67,595) Accumulated losses brought forward (424,441) Under IFRS accounting standards, the consolidated ne
Slide 30: Agenda item 3: Discharge of Board and Management
Agenda item 3 Discharge of the Members of the Board of Directors and the Executive Management ■ The Board proposes that all Members of the Board and of the Executive Management be discharged from their liabilities for their activities in the financial year 2025 NASDAQ: ACIU | AGM Presentation, June
Slide 31: Agenda item 4.1: Board compensation
Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Management 4.1 Binding Vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2026 to the AGM 2027 ■ The Board proposes the approval of the total maximum amount of compensation f
Slide 32: Agenda item 4.2: Executive Management compensation
Agenda item 4 Compensation for the Members of the Board of Directors and the Executive Management 4.2 Binding Vote on Maximum Aggregate Compensation for Members of the Executive Management for the Financial Year 2027 ■ The Board proposes the approval of the total maximum amount of compensation for t
Slide 33: Agenda item 5.1: Re-election of Board of Directors
Agenda item 5 Re-Elections 5.1 Re-Elections of Members and the Chair of the Board of Directors ■ The Board proposes that each of the following persons be re-elected for a term of office until the end of the AGM 2027: ■ Martin Zügel as Member and Chair of the Board and as Members of the Board: ■ René
Slide 34: Agenda item 5.2: Re-election of Compensation Committee
Agenda item 5 Re-Elections 5.2 Re-Elections of Members of the Compensation, Nomination and Corporate Governance Committee ■ The Board proposes that: ■ Monika Bütler ■ Roy Twyman be re-elected as Members of the Compensation, Nomination and Corporate Governance Committee for a term of office until the
Slide 35: Agenda item 5.3: Re-election of Statutory Auditors
Agenda item 5 Re-Elections 5.3 Re-Election of the Statutory Auditors ■ The Board proposes that PricewaterhouseCoopers SA, in Lausanne, Switzerland, be re-elected as Statutory Auditors for the financial year 2026. NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or repr
Slide 36: Agenda item 5.4: Re-election of Independent Proxy
Agenda item 5 Re-Elections 5.4 Re-Election of the Independent Proxy ■ The Board proposes that Reymond & Associés Attorneys in Lausanne, Switzerland be re-elected as Independent Proxy for a term of office until the end of the AGM 2027. NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune.
Slide 37: Agenda item 6.1: Capital Band
Agenda item 6 Changes in the Articles of Association 6.1 Capital Band (Article 3a) ■ The Board proposes to introduce a capital band with an upper limit of CHF 2,862,500.00 and a lower limit of CHF 2,202,018.50, authorizing the Board to increase and/or decrease the Company’s share capital one or seve
Slide 38: Agenda item 6.2: Conditional Share Capital
Agenda item 6 Changes in the Articles of Association 6.2 Increase of Conditional Share Capital for Employee-Benefit Plans (Art. 3c) ■ The Board proposes to increase the conditional share capital for employee benefit plans from CHF 86,683.80 to CHF 150,000.00 and accordingly to amend art. 3c of the A
Slide 39: We thank you for your attendance and continued support
We thank you for your attendance and your continued support. NASDAQ: ACIU | AGM Presentation, June 11, 2026 © 2026 AC Immune. Not to be used or reproduced without permission 39
Slide 40: Back-up
Back-up
Slide 41: Agenda item 6.1: Proposed Article 3a
Agenda item 6.1 Proposed Article 3a 1. The Company has a capital band ranging from CHF 2,202,018.50 corresponding to a) if the issue price of the new registered shares is determined by reference to 110,100,925 registered shares with a par value of CHF 0.02 each, to be fully paid the market price (wi
Slide 42: Agenda item 6.1: Proposed Article 3a (cont'd)
Agenda item 6.1 Proposed Article 3a (cont’d) 3. The subscription to and acquisition of new registered shares and any subsequent transfers of their ownership shall be subject to the restrictions specified in Article 4 of the Articles of Association. 4. Capital reductions may be performed both by redu
Slide 43: Agenda item 6.2: Proposed Article 3c
Agenda item 6.2 Proposed Article 3c 1. The share capital of the Company shall be increased by an amount not exceeding CHF 150,000.00 through the issue of a maximum of 7,500,000 registered shares, payable in full, each with a nominal value of CHF 0.02, in connection with the exercise of option rights